t
Feedback plc held its Annual General Meeting on October 13, 2025, where all 13 proposed resolutions were duly passed by shareholders. These resolutions included the re-election of all named directors, the re-appointment of Price Bailey LLP as auditor, and the authorization for directors to allot equity securities. Votes in favour of the resolutions ranged from 99.68% to 99.999%, with 43,814,779 ordinary shares in issue as of the meeting date.
| Date | 13 Oct 2025 |
| Time | 16:04:50 |
| Category | AGMs and other meetings |
| ID | 1620D |
Feedback plc
Result of Annual General Meeting
Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the clinical infrastructure specialist, announces that at the Annual General Meeting held today all resolutions were duly passed.
The results of the poll (including proxy votes on the resolutions) are included below.
|
Resolutions |
Votes for* |
% of votes cast** |
Votes against |
% of votes cast** |
Votes withheld*** |
|
1) To receive the Annual Report and Accounts for the financial year ended 31 May 2025 |
17,771,063 |
99.999% |
120 |
0.001% |
86 |
|
2) To accept the Directors' Remuneration Report for the financial year ended 31 May 2025 |
17,763,723 |
99.96% |
7,386 |
0.04% |
160 |
|
3) To re-elect Adam Denning as a director of the Company |
17,756,812 |
99.97% |
6,120 |
0.03% |
8,337 |
|
4) To re-elect Annemijn Eschauzier as a director of the Company |
17,756,546 |
99.96% |
6,386 |
0.04% |
8,337 |
|
5) To re-elect Dr. Tom Oakley as a director of the Company |
17,763,989 |
99.96% |
7,120 |
0.04% |
160 |
|
6) To re-elect Anesh Patel as a director of the Company |
17,764,989 |
99.97% |
6,120 |
0.03% |
160 |
|
7) To re-elect Philipp Prince as a director of the Company |
17,758,796 |
99.98% |
4,136 |
0.02% |
8,337 |
|
8) To re-elect Professor Rory Shaw as a director of the Company |
17,719,573 |
99.71% |
51,536 |
0.29% |
160 |
|
9) To re-appoint Price Bailey LLP as auditor of the Company |
17,770,989 |
99.999% |
120 |
0.001% |
160 |
|
10) To authorise the Directors to determine the fees payable to the auditor |
17,770,989 |
99.999% |
120 |
0.001% |
160 |
|
11) To authorise the Directors to allot Equity Securities within the parameters set out in the Notice
|
17,720,805 |
99.72% |
50,304 |
0.28% |
160 |
|
Special Resolutions |
|||||
|
12) Subject to the passing of resolution 11, to authorise the Directors to allot Equity Securities for cash as if Section 561 of the CA 2006 did not apply |
17,706,894 |
99.68% |
56,038 |
0.32% |
8,337 |
|
13) Subject to the passing of resolution 11 and in addition to resolution 12, to authorise the Directors to allot Equity Securities for cash as if Section 561 of the CA 2006 did not apply |
17,707,894 |
99.69% |
55,038 |
0.31% |
8,337 |
Notes:
* "Votes For" include votes giving the Chairman discretion.
** Percentages exclude "Votes Withheld".
*** "Votes Withheld" are not votes in law and do not count in the number of votes counted for or against a resolution.
As at 13 October, there were 43,814,779 ordinary shares in issue. Shareholders are entitled to one vote per share.
The full text of each resolution is available in the Notice of Annual General Meeting, published on the Company's website.
-Ends-
Enquiries:
|
Feedback plc Tom Oakley, CEO Anesh Patel, CFO |
+44 (0) 20 3997 7634 |
|
|
|
|
Panmure Liberum Limited (NOMAD and Broker) Emma Earl/ Mark Rogers (Corporate Finance) Rupert Dearden (Corporate Broking) |
+44 (0)20 7886 2500 |
|
|
|
|
Walbrook PR Ltd; |
Tel: 020 7933 8780 or [email protected] |
|
Nick Rome/Joe Walker |
07748 325 236 or 07407 020 470 |
About Feedback plc
Feedback plc liberates the data and knowledge from multiple healthcare IT systems and delivers better workflow to enable clinicians to communicate, collaborate and provide the best healthcare for their patients. We connect care settings with diagnostic and other relevant data to drive better, faster, safer decision that improve outcomes for patients.
By linking different clinical systems together into a seamless view of the patient, we can streamline patient pathways and deliver a digital health and diagnostics record across multiple care providers.
Bleepa® is our communication and collaboration platform that displays clinical results at a certified and regulated quality, which enables multi-disciplinary team working and diagnostic-enhanced advice and guidance. CareLocker® is our patient-facing platform that gives patients access and control over their diagnostic and other clinical data.
The Company has a number of growth opportunities domestically and internationally across a range of public and private healthcare markets including the NHS. Our highly scalable software-as-a-service (SaaS) based model is expected to provide increasing levels of revenue visibility as the Company grows its customer base.